Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 1;28(21):4714–4723. doi: 10.1158/1078-0432.CCR-22-0749

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Survival analysis according to (A) ATR amplification (median PFS 5.0 months vs.10.9 months, respectively for samples with ATR-amplification and those without, respectively). B, Cox model same as in Fig. 2E but with the additional covariate of ATR amplification. HRD is defined as panel-Sig3+ and/or BRCA1/2mut. “Prior N Tx” refers to number of prior lines of therapy. — Survival analysis according to (A) ATR amplification (median PFS 5.0 months vs.10.9 months, respectively, for samples with ATR amplification and those without). B, Cox model same as in Fig. 2E but with the additional covariate of ATR amplification. HRD is defined as panel-Sig3+ and/or BRCA1/2mut. “Prior N Tx” refers to number of prior lines of therapy.